The metabolic role of prolactin has become a relevant topic in recent years. It has been established that an excess of prolactin (PRL) leads to increased body weight, obesity, metabolic syndrome, and disturbances in glucose-insulin and lipid profiles. This is mainly attributed to the suppression of physiological dopaminergic tone. Research has shown that prolactin receptors and dopamine receptors are expressed in both pancreatic β-cells and adipose tissue, confirming the essential role of prolactin and dopamine in peripheral metabolic regulation. Medical treatment with dopamine agonists, such as bromocriptine and cabergoline, helps reduce metabolic syndrome and obesity, as well as significantly improve glucose-insulin and lipid profiles.

Overweight, glucose, insulin, lipid profile, hyperprolactinemia, HOMA-IR

Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. The effectsof hyperprolactinemia and its control on metabolic diseases. Expert Rev EndocrinolMetab (2018) 13(2):99–106. doi: 10.1080/17446651.2018.1434412

Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus onprolactin as a metabolic hormone. Trends Endocrinol Metab (2006) 17(3):110–6.doi: 10.1016/j.tem.2006.02.005

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM,Schlechte JA, et al. Endocrine society. diagnosis and treatment ofhyperprolactinemia: an endocrine society clinical practice guideline. J ClinEndocrinol Metab (2011) 96(2):273–88. doi: 10.1210/jc.2010-1692

Baptista T, Lacruz A, de Mendoza S, Mendoza Guillén JM, Silvera R, AngelesF, et al. Body weight gain after administration of antipsychotic drugs: correlationwith leptin, insulin and reproductive hormones. Pharmacopsychiatry (2000) 33(3):81–8. doi: 10.1055/s-2000-8451

Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, CasanuevaF, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated withbromocriptine. Eur J Endocrinol (2002) 147(1):77–84. doi: 10.1530/eje.0.1470077

Greenman Y, Tordjman K, Stern N. Increased body weight associated withprolactin secreting pituitary adenomas: weight loss with normalization of prolactinlevels. Clin Endocrinol (Oxf) (1998) 48(5):547–53. doi: 10.1046/j.1365-2265.1998.00403.x

Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, et al.Gender differences in the prevalence, clinical features and response to cabergolinein hyperprolactinemia. Eur J Endocrinol (2003) 148(3):325–31. doi: 10.1530/je.0.1480325

Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation ofrelease and putative functions. Diabetes Obes Metab (2007) 9(4):464–76. doi:10.1111/j.1463-1326.2006.00671.x

Strader AD, Buntin JD. Changes in agouti-related peptide during the ringdove breeding cycle in relation to prolactin and parental hyperphagia. JNeuroendocrinol (2003) 15(11):1046–53. doi: 10.1046/j.1365-2826.2003.01092.x10. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevatedhypothalamic neuropeptide y and corticotropin-releasing hormone, body weightgain, and hyperglycemia in ob/ob mice. Neuroendocrinology (2000) 71(1):68–78.doi: 10.1159/000054522

Macotela Y, Triebel J, Clapp C. Time for a new perspective on prolactin inmetabolism. Trends Endocrinol Metab (2020) 31(4):276–86. doi: 10.1016/j.tem.2020.01.004

Sorenson RL, Brelje TC. Adaptation of islets of langerhans to pregnancy:beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones.Horm Metab Res (1997) 29(6):301–7. doi: 10.1055/s-2007-979040

Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL. Regulation ofglucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol (2007) 193(3):367–81.doi: 10.1677/JOE-07-0043

Nagano M, Kelly PA. Tissue distribution and regulation of rat prolactinreceptor gene expression. quantitative analysis by polymerase chain reaction. J BiolChem (1994) 269(18):13337–45.

Møldrup A, Petersen ED, Nielsen JH. Effects of sex and pregnancyhormones on growth hormone and prolactin receptor gene expression ininsulin-producing cells. Endocrinology (1993) 133(3):1165–72. doi: 10.1210/endo.133.3.8365359

Brelje TC, Stout LE, Bhagroo NV, Sorenson RL. Distinctive roles forprolactin and growth hormone in the activation of signal transducer andactivator of transcription 5 in pancreatic islets of langerhans. Endocrinology(2004) 145(9):4162–75. doi: 10.1210/en.2004-0201

Vasavada RC, Garcia-Ocaña A, Zawalich WS, Sorenson RL, Dann P, SyedM, et al. Targeted expression of placental lactogen in the beta cells of transgenicmice results in beta cell proliferation, islet mass augmentation, and hypoglycemia. JBiol Chem (2000) 275(20):15399–406. doi: 10.1074/jbc.275.20.15399

Landgraf R, Landraf-Leurs MM, Weissmann A, Hörl R, von Werder K,Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia (1977) 13(2):99–104.doi: 10.1007/BF00745135

Johnston DG, Alberti KG, Nattrass M, Burrin JM, Blesa-Malpica G, Hall K,et al. Hyperinsulinaemia in hyperprolactinemic women. Clin Endocrinol (Oxf)(1980) 13(4):361–8. doi: 10.1111/j.1365-2265.1980.tb03397.x

Schernthaner G, Prager R, Punzengruber C, Luger A. Severehyperprolactinaemia is associated with decreased insulin binding in vitro andinsulin resistance in vivo. Diabetologia (1985) 28(3):138–42. doi: 10.1007/BF00273860

Atmaca A, Bilgici B, Ecemis GC, Tuncel OK. Evaluation of body weight,insulin resistance, leptin and adiponectin levels in premenopausal women withhyperprolactinemia. Endocrine (2013) 44(3):756–61. doi: 10.1007/s12020-013-9931-0

Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM.Longitudinal changes in maternal serum leptin concentrations, bodycomposition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol1998) 178(5):1010–5. doi: 10.1016/S0002-9378(98)70540-X

Butte NF, Hopkinson JM, Nicolson MA. Leptin in human reproduction:serum leptin levels in pregnant and lactating women. J Clin Endocrinol Metab(1997) 82(2):585–9. doi: 10.1210/jcem.82.2.3731

Balci H, Akgun-Dar K, Gazioglu N, Kapucu A, Bolayirli M, Oz B. Therelationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines inpatients with hyperprolactinemia. Pituitary (2009) 12(3):170–6. doi: 10.1007/s11102-008-0140-4

Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Braindopamine and obesity. Lancet (2001) 357(9253):354–7. doi: 10.1016/S0140-6736(00)03643-6.